Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Hold” by Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has earned an average recommendation of “Hold” from the eleven research firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $8.1250.

NMRA has been the topic of a number of research analyst reports. Leerink Partners began coverage on shares of Neumora Therapeutics in a research note on Monday, January 12th. They set an “outperform” rating and a $8.00 price objective on the stock. Stifel Nicolaus increased their price target on shares of Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a research report on Monday, November 17th. Guggenheim raised Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Monday, October 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Thursday, January 22nd. Finally, Needham & Company LLC lifted their target price on Neumora Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th.

Neumora Therapeutics Price Performance

Shares of NASDAQ NMRA opened at $1.96 on Friday. The company has a quick ratio of 6.85, a current ratio of 6.85 and a debt-to-equity ratio of 0.15. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $3.25. The business has a 50 day moving average price of $2.00 and a two-hundred day moving average price of $1.99. The firm has a market cap of $327.50 million, a PE ratio of -1.33 and a beta of 3.20.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Thursday, November 6th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Sell-side analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 114,703 shares of the business’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $2.68, for a total transaction of $307,404.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 26.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors have recently modified their holdings of the business. Legacy Private Trust Co. lifted its holdings in Neumora Therapeutics by 35.7% in the fourth quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock worth $34,000 after acquiring an additional 5,000 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its position in shares of Neumora Therapeutics by 10.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock worth $117,000 after purchasing an additional 6,233 shares during the period. Invesco Ltd. lifted its holdings in shares of Neumora Therapeutics by 6.8% in the 2nd quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock worth $97,000 after purchasing an additional 8,383 shares during the last quarter. CWM LLC boosted its position in Neumora Therapeutics by 41.8% during the 2nd quarter. CWM LLC now owns 35,750 shares of the company’s stock valued at $26,000 after purchasing an additional 10,537 shares during the period. Finally, Virtu Financial LLC bought a new position in Neumora Therapeutics during the 3rd quarter worth $31,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.